← All trials
NCT05642845
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 11, 2022
- Primary completion
- Nov 29, 2022
- Completion date
- Dec 20, 2022
- First posted
- Dec 8, 2022
- Last posted
- Dec 8, 2022
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pharmtechnology LLCLead sponsor
- CRO ClinPharmInvestCollaborator
- CRO ClinPharmInvestOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.